Open Access

Successful use of pazopanib for treatment of refractory metastatic hemangiopericytoma

  • Su Jin Lee1,
  • Seung Tae Kim1,
  • Se Hoon Park1,
  • Yoon La Choi2,
  • Jae Berm Park3,
  • Sung-Joo Kim3 and
  • Jeeyun Lee1Email author
Clinical Sarcoma Research20144:13

https://doi.org/10.1186/2045-3329-4-13

Received: 2 September 2014

Accepted: 18 September 2014

Published: 24 September 2014

Abstract

Hemangiopericytoma is a rare disease entity of soft-tissue sarcoma (STS) that can be cured with surgical resection. In cases of inoperable recurrence or metastasis, palliative chemotherapy is indicated, though there is currently no approved chemotherapy regimen. Therefore new treatment regimens are needed.

We describe three cases of metastatic hemangiopericytoma. In the first case, five lines of chemotherapeutic agents were used unsuccessfully in a patient with a 12-year history of metastatic hemangiopericytoma. After one cycle of pazopanib therapy, however, chest radiography showed a decrease in tumor volume of more than 30%. A marked decrease in FDG uptake on PET CT was also noted, and the patient is now on her 5th month of pazopanib therapy. The second case is a patient with a brain hemangiopericytoma with multiple liver, lung, and bone metastases. Pazopanib induced radiologic stabilization of metastatic disease over the course of 8 months. The third case is a patient with a retroperitoneal hemangiopericytoma with pleural and peri-renal metastases. For more than 8 months, he has exhibited stable disease with pazopanib treatment.

Pazopanib may be useful for treatment of metastatic hemangiopericytoma, though further studies are needed to confirm the efficacy of this medication and to investigate its molecular mechanism of action.

Keywords

Hemangiopericytoma Pazopanib Anti-angiogenic agent

Introduction

Hemangiopericytoma was first described in 1942 by Stout and Murray[1] as a distinct soft tissue neoplasm, presumably of pericyte origin, exhibiting a characteristic well-developed “staghorn” branching vascular pattern. However, hemangiopericytoma has been reclassified as a fibroblastic neoplasm similar to a solitary fibrous tumor (SFT)[2, 3]. It typically affects adults aged 20–70 years, with a median age in the 40s[4, 5]. Common sites of involvement include the lower extremities, retroperitoneum/pelvis, lung/pleura, and meninges, though it may be found in virtually any part of the body[4, 6].

Several patients with hemangiopericytoma have been successfully managed with surgical resection. However, approximately 15-20% of patients develop local recurrence or distant metastasis[4], and additional resections are not always feasible. The most common sites of metastasis are the lung, bone, and liver. Although there is no standard treatment for patients with advanced disease that is unresectable, anthracycline and ifosfamide-based chemotherapies are widely used.

Here, we describe three patients with metastatic hemangiopericytomas who were treated with pazopanib. The first patient achieved a partial response after one month of pazopanib therapy, while the second and third patients had stable disease over the course of 8 months of treatment based on RECIST v1.1[7].

Case presentation

The first patient was a 49-year-old female diagnosed in 2001 with multiple lung metastases from a hemangiopericytoma of an unknown primary site. After 6 cycles of first-line chemotherapy (doxorubicin and ifosfamide), her tumor response was classified as ‘stable disease’, and metastatectomy of the lung was performed in both 2002 and 2004. In 2005, a CT-scan showed multiple lung metastases that were inoperable. Due to the slow progression of her disease, she did not receive palliative chemotherapy until 2009. Beginning in 2009, she had nine cycles of second line chemotherapy (docetaxel/gemcitabine), twenty cycles of third line chemotherapy (everolimus), one cycle of fourth line chemotherapy (dacarbazine/cisplatin), and eight cycles of fifth line chemotherapy (ifosfamide, etoposide, cisplatin). In January 2014, the patient presented with pulmonary progression of disease, and was started on pazopanib treatment (800 mg daily). After one cycle of pazopanib, chest radiography showed a tumor response and the patient reported symptomatic improvement. After three months of pazopanib treatment, PET-CT and chest CT showed a partial response with more than a 50% decrease in tumor volume and a marked decrease in FDG uptake (maximum SUV for pelvic wall mass from 5.2 to 1.5 and right upper lung mass from 5.9 to 2.0) (Figure 1). She is now on her 5th month of pazopanib therapy, and continues to maintain a ‘partial response’.
Figure 1

Response to pazopanib therapy in case 1. a. PET-CT at baseline and after 3 months of pazopanib treatment. b. Chest radiograph at baseline and after 4.5 months of pazopanib treatment.

The second patient was a 52-year-old male who was diagnosed with a brain hemangiopericytoma after craniotomy and tumor removal in 2003. The patient experienced several post-operative recurrences in the brain that were treated with gamma-knife surgery. In 2011, recurrence was detected in the liver, and he underwent left hemihepatectomy. Six months later, another recurrence in the liver was treated with radiofrequency ablation. In July 2012, he developed metastases to the lung, liver, and pancreas, and first-line chemotherapy was administered (ifosfamide/etoposide/cisplatin). After 4 cycles of chemotherapy, a CT scan showed ‘stable disease’, but the patient was lost to follow-up. Several months later, the patient developed back pain, and metastasis to the spine at L1 was identified and treated with stereotactic radiation therapy. Pazopanib 800 mg daily was started in August 2013, and he has exhibited stable disease of lung, liver and pancreas over the course of 9 months of treatment. Except grade 1 diarrhea, there was no adverse event.

A third patient was a 54-year-old male patient with a retroperitoneal hemangiopericytoma that was diagnosed after resection of the mass in 1998. Adjuvant radiotherapy was done after surgery. Fifteen years later, multiple pleural, peri-renal and abdominal wall metastases were confirmed on a biopsy of one of the pleural masses. Palliative first line chemotherapy (ifosfamide/etoposide/cisplatin) was administered for 4 cycles, and his tumor response was classified as ‘stable disease’. Second line chemotherapy (docetaxel/gemcitabine) was then administered, and again the patient was classified as having ‘stable disease’. After 6 cycles of chemotherapy, however, his disease especially in lung progressed. He has since been taking third line pazopanib for eight months, and has again achieved ‘stable disease’. He was also tolerable to pazopanib 800 mg daily dose and no dose reduction was needed.

Discussion

Although anthracycline-based therapies are frequently used, limited data is available regarding the efficacy of systemic chemotherapy in cases of advanced hemangiopericytoma. A few cases of hemangiopericytomas that have responded to chemotherapeutic agents have been reported, but no systematic reviews or clinical trials to date have identified an effective systemic treatment regimen, and the effects of these agents on PFS and OS remain uncertain[4, 810].

The rich vascular characteristics of hemangiopericytomas and IHC expression of VEGF in these tumor cells[1113] have prompted clinicians to try antiangiogenic therapies. Case reports have suggested that interferon-α may play a role in achieving disease stabilization in patients with hemangiopericytoma[9, 14]. Park et al. reported retrospective data on use of temozolomide and bevacizumab in 14 patients with hemangiopericytoma/malignant solitary fibrous tumor in 2011[15]. Eleven of 14 patients (79%) demonstrated Choi PR, and two patients achieved stable disease. The best response observed, as measured in RECIST, showed one PR and 13 cases of stable disease. The precise mechanisms by which temozolomide and bevacizumab exert their effects on hemangiopericytoma are not clear[5], but this regimen showed promising efficacy in that study.

Several case reports and retrospective studies suggested that imatinib[16, 17], sorafenib[18], and sunitinib[1821] could achieve long-lasting stable disease, although they did not induce a RECIST response. De Pas et al. reported a case in which clinical benefit was observed for 21-months with use of imatinib, which induced expression of PDGFR-α and PEGFR-ß[17].

Pazopanib (GlaxoSmithKline, Stevenage, UK) is a novel oral multi-targeted tyrosine kinase inhibitor with a wide range of activities that are mediated through VEGFR types 1, 2, and 3, platelet-derived growth factor receptors α and ß, and stem-cell factor receptor (c-Kit)[22, 23]. A phase III trial of pazopanib showed PFS gain when compared with placebo in patients with metastatic non-adipocytic soft-tissue sarcoma (STS) after standard chemotherapy[24]. Based on that study, pazopanib was approved and has been used in most cases of relapsed or refractory STS. However, the efficacy of pazopanib in specific types of STS, especially hemangiopericytoma, is unknown. A recent subgroup analysis reported that four of seven patients with solitary fibrous tumors exhibited longer-term PFS and OS with pazopanib treatment[25, 26].

The first case discussed is the first report of a RECIST response with use of pazopanib in patients with hemangiopericytoma. The precise mechanism by which pazopanib exerts its effect on hemangiopericytomas is poorly understood and requires further investigation.

Conclusion

These three cases demonstrate that pazopanib may have clinical efficacy in patients with metastatic hemangiopericytoma, and thus pazopanib should be considered as potential treatment option for these patients.

Consent

Written informed consent was obtained from the patients for the publication of this report and any accompanying images.

Declarations

Authors’ Affiliations

(1)
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine
(2)
Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine
(3)
Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine

References

  1. Stout AP, Murray MR: Hemangiopericytoma: a vascular tumor featuring zimmermann’s pericytes. Ann Surg. 1942, 116: 26-33. 10.1097/00000658-194207000-00004PubMed CentralView ArticlePubMedGoogle Scholar
  2. Fletcher CD: The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology. 2006, 48: 3-12. 10.1111/j.1365-2559.2005.02284.xView ArticlePubMedGoogle Scholar
  3. Gengler C, Guillou L: Solitary fibrous tumour and haemangiopericytoma: evolution of a concept. Histopathology. 2006, 48: 63-74. 10.1111/j.1365-2559.2005.02290.xView ArticlePubMedGoogle Scholar
  4. Spitz FR, Bouvet M, Pisters PW, Pollock RE, Feig BW: Hemangiopericytoma: a 20-year single-institution experience. Ann Surg Oncol. 1998, 5: 350-355. 10.1007/BF02303499View ArticlePubMedGoogle Scholar
  5. Park MS, Araujo DM: New insights into the hemangiopericytoma/solitary fibrous tumor spectrum of tumors. Curr Opin Oncol. 2009, 21: 327-331. 10.1097/CCO.0b013e32832c9532View ArticlePubMedGoogle Scholar
  6. Espat NJ, Lewis JJ, Leung D, Woodruff JM, Antonescu CR, Shia J, Brennan MF: Conventional hemangiopericytoma: modern analysis of outcome. Cancer. 2002, 95: 1746-1751. 10.1002/cncr.10867View ArticlePubMedGoogle Scholar
  7. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009, 45: 228-247. 10.1016/j.ejca.2008.10.026View ArticlePubMedGoogle Scholar
  8. Beadle GF, Hillcoat BL: Treatment of advanced malignant hemangiopericytoma with combination adriamycin and DTIC: a report of four cases. J Surg Oncol. 1983, 22: 167-170. 10.1002/jso.2930220306View ArticlePubMedGoogle Scholar
  9. Chamberlain MC, Glantz MJ: Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma. Neurosurgery. 2008, 63: 720-726. author reply 726–727,View ArticlePubMedGoogle Scholar
  10. Galanis E, Buckner JC, Scheithauer BW, Kimmel DW, Schomberg PJ, Piepgras DG: Management of recurrent meningeal hemangiopericytoma. Cancer. 1998, 82: 1915-1920. 10.1002/(SICI)1097-0142(19980515)82:10<1915::AID-CNCR15>3.0.CO;2-WView ArticlePubMedGoogle Scholar
  11. Hatva E, Bohling T, Jaaskelainen J, Persico MG, Haltia M, Alitalo K: Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas. Am J Pathol. 1996, 148: 763-775.PubMed CentralPubMedGoogle Scholar
  12. Dietzmann K, von Bossanyi P, Warich-Kirches M, Kirches E, Synowitz HJ, Firsching R: Immunohistochemical detection of vascular growth factors in angiomatous and atypical meningiomas, as well as hemangiopericytomas. Pathol Res Pract. 1997, 193: 503-510. 10.1016/S0344-0338(97)80104-5View ArticlePubMedGoogle Scholar
  13. Park MS, Ravi V, Araujo DM: Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. Curr Opin Oncol. 2010, 22: 351-355. 10.1097/CCO.0b013e32833aaad4View ArticlePubMedGoogle Scholar
  14. Lackner H, Urban C, Dornbusch HJ, Schwinger W, Kerbl R, Sovinz P: Interferon alfa-2a in recurrent metastatic hemangiopericytoma. Med Pediatr Oncol. 2003, 40: 192-194. 10.1002/mpo.10122View ArticlePubMedGoogle Scholar
  15. Park MS, Patel SR, Ludwig JA, Trent JC, Conrad CA, Lazar AJ, Wang WL, Boonsirikamchai P, Choi H, Wang X, Benjamin RS, Araujo DM: Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer. 2011, 117: 4939-4947. 10.1002/cncr.26098PubMed CentralView ArticlePubMedGoogle Scholar
  16. Rossi G, Schirosi L, Giovanardi F, Sartori G, Paci M, Cavazza A: Pleural malignant solitary fibrous tumor with sarcomatous overgrowth showing PDGFRbeta mutation. Chest. 2006, 130: 581-583. 10.1378/chest.130.2.581View ArticlePubMedGoogle Scholar
  17. De Pas T, Toffalorio F, Colombo P, Trifiro G, Pelosi G, Vigna PD, Manzotti M, Agostini M, de Braud F: Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura. J Thorac Oncol. 2008, 3: 938-941. 10.1097/JTO.0b013e3181803f08View ArticlePubMedGoogle Scholar
  18. Domont J, Massard C, Lassau N, Armand JP, Le Cesne A, Soria JC: Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour. Invest New Drugs. 2010, 28: 199-202. 10.1007/s10637-009-9249-1View ArticlePubMedGoogle Scholar
  19. Stacchiotti S, Negri T, Palassini E, Conca E, Gronchi A, Morosi C, Messina A, Pastorino U, Pierotti MA, Casali PG, Pilotti S: Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response. Mol Cancer Ther. 2010, 9: 1286-1297. 10.1158/1535-7163.MCT-09-1205View ArticlePubMedGoogle Scholar
  20. Delgado M, Perez-Ruiz E, Alcalde J, Perez D, Villatoro R, Rueda A: Anti-angiogenic treatment (sunitinib) for disseminated malignant haemangiopericytoma: a case study and review of the literature. Case Rep Oncol. 2011, 4: 55-59. 10.1159/000324487PubMed CentralView ArticlePubMedGoogle Scholar
  21. Mulamalla K, Truskinovsky AM, Dudek AZ: Rare case of hemangiopericytoma responds to sunitinib. Transl Res. 2008, 151: 129-133. 10.1016/j.trsl.2007.12.007View ArticlePubMedGoogle Scholar
  22. Kumar R, Crouthamel MC, Rominger DH, Gontarek RR, Tummino PJ, Levin RA, King AG: Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer. 2009, 101: 1717-1723. 10.1038/sj.bjc.6605366PubMed CentralView ArticlePubMedGoogle Scholar
  23. Hamberg P, Verweij J, Sleijfer S: (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist. 2010, 15: 539-547. 10.1634/theoncologist.2009-0274PubMed CentralView ArticlePubMedGoogle Scholar
  24. van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schoffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P: Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012, 379: 1879-1886. 10.1016/S0140-6736(12)60651-5View ArticlePubMedGoogle Scholar
  25. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schoffski P, Collin F, Pandite L, Marreaud S, De Brauwer A, van Glabbeke M, Verweij J, Blay JY: Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009, 27: 3126-3132. 10.1200/JCO.2008.21.3223View ArticlePubMedGoogle Scholar
  26. Kasper B, Sleijfer S, Litiere S, Marreaud S, Verweij J, Hodge RA, Bauer S, Kerst JM, van der Graaf WT: Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European organisation for research and treatment of cancer (EORTC) clinical trials 62043 and 62072. Ann Oncol. 2014, 25: 719-724. 10.1093/annonc/mdt586PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Lee et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement